TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05213312
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 175 mg/m2 on DAY2, with cisplatin Q3W, ivgtt for two cycles
Study: NCT04776096
Drug: Bepotastine Besilate 1.5% PF
DrugBank: Bepotastine (DB04890)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bepotastine besilate 1,5% Preservative free ophthalmic solution
Study: NCT04776096
Drug: Olopatadine Hydrochloride 0.2% BAK
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olopatadine hydrochloride 0.2% with BAK as preservative
Study: NCT05481905
Drug: ENX-101
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive treatment to current antiseizure medication
Study: NCT00002095
Drug: Ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01797666
Drug: Torrent's Pioglitazone Hydrochloride Tablets 45 mg
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05305508
Drug: Mannitol
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The comparator (placebo, Mannitol 500 mg) will be administered orally twice a day for 7 days.
Study: NCT05794659
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3-week interval, 6 cycles in total
Study: NCT05794659
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-week interval, 6 cycles in total
Study: NCT05794659
Drug: rhuGM-CSF(Granulocyte-Macrophage Colony-Stimulating Factor)
Normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: i.d. (3-week interval, 3 cycles in total)
Study: NCT00502294
Drug: Visilizumab (HuM291; Nuvion®)
Normalized name: Visilizumab
DrugBank: Visilizumab (DB12053)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06699121
Drug: LB-P8 low-dose
Normalized name: ethinyl estradiol
DrugBank: LB-P8 (DB18535)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule QD (1×10\^10 CFU/day) oral administration
Study: NCT06699121
Drug: LB-P8 high-dose
Normalized name: LB-P8
DrugBank: LB-P8 (DB18535)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule QD (1×10\^11 CFU/day) oral administration
Study: NCT06700083
Drug: SHR-6934 injection
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-6934 injection
Study: NCT06442748
Drug: Levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam is usually preferred in brain tumor-related epilepsy. Levetiracetam is a second-generation antiepileptic drug that binds to synaptic vesicle glycoprotein SV2A, which interferes with the release of neurotransmitters from the synaptic vesicle and control seizure by multiple mechanisms.
Study: NCT05320094
Drug: Mavacamten
Normalized name: Mavacamten
DrugBank: Mavacamten (DB14921)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05600114
Drug: Cannabidiol oral solution
Normalized name: cannabidiol Oral Solution
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CBD 150 mg BID
Study: NCT05600114
Drug: Cannabidiol oral solution
Normalized name: cannabidiol Oral Solution
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CBD 300 mg BID
Study: NCT04975217
Drug: Fecal Microbiota Transplantation Capsule
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT05132049
Drug: DA-5211
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose administration (DA-5211 one tablet once a day)
Study: NCT04935177
Drug: Imlifidase
Normalized name: Imlifidase
DrugBank: Imlifidase (DB15258)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
Study: NCT04935177
Drug: IVIg
Normalized name: hIVIG
DrugBank: Anti-SARS-CoV-2 immunoglobulin (DB16360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIg prepared from a pool of immunoglobulins from the plasma of thousands of healthy donors is administered in accordance with respective site's standard procedure for desensitization.
Study: NCT04935177
Drug: Anti-CD20 antibodies
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab and other anti-CD20 according to the respective site's standard procedure for desensitization.
Study: NCT04935177
Drug: Eculizumab
Normalized name: Eculizumab
DrugBank: Eculizumab (DB01257)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Eculizumab according to the respective site's standard procedure for desensitization.
Study: NCT06562907
Drug: GS-4571
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally
Study: NCT06562907
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04758949
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 240 mg administered intravenously every 2 weeks prior to surgery.
Study: NCT04860505
Drug: Biktarvy
Normalized name: Biktarvy
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Biktarvy (200mg) is an oral combination anti-HIV medication that contains the drugs tenofovir alafenamide, emtricitabine, and bictegravir.
Study: NCT04767815
Drug: Diet A group
Normalized name: meningococcal group A polysaccharide
DrugBank: Meningococcal polysaccharide vaccine group A (DB13889)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting + DWN12088 200 mg
Study: NCT04767815
Drug: Diet C group
Normalized name: meningococcal group C polysaccharide
DrugBank: Meningococcal polysaccharide vaccine group C (DB13890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 hours after a high-fat meal + DWN12088 200 mg
Study: NCT05891132
Drug: 10 ml of lidocaine 2%
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 ml of lidocaine 2% for perineal infiltration at the time of crowning
Study: NCT05891132
Drug: lidocaine prilocaine cream 15gm
Normalized name: lidocaine / prilocaine Topical Cream
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine prilocaine cream, an eutectic mixture, is composed of Lidocaine-25 mg, Prilocaine-25 mg, Arlactone 289 -19 mg, Carbopol-10 mg, Sodium hydroxide to make a pH of 9.6 mg and purified water to produce l gram.
Study: NCT06364852
Drug: LY007
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FC and LY007 infusion
Study: NCT05782894
Drug: Remimazolam besylate
Normalized name: Remimazolam Besylate
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0\~2.0mg/kg/h
Study: NCT05782894
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.3\~4.0mg/kg/h
Study: NCT05957510
Drug: Serplulimab
Normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: serplulimab 300mg, d1, q3w, iv. etoposide 100 mg/m2, d1-3, q3w, iv. carboplatin AUC 5 (up to 750mg), d1, q3w, iv.
Study: NCT05966012
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recent data suggests that antifibrinolytics like tranexamic acid (TXA) might be able to lessen the inflammation of the nervous system caused by surgery and CPB through the inhibition of plasmin production, thereby stabilising the blood brain barrier.
Study: NCT04913103
Drug: Polatuzumab vedotin
Normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: treatment by a study drug polatuzumab-vedotin, i.v.
Study: NCT04913103
Drug: Bendamustine Hydrochloride
Normalized name: Bendamustine Hydrochloride
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: treatment by a study drug bendamustin i.v.
Study: NCT04913103
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: treatment by a study drug rituximab, i.v.
Study: NCT05824871
Drug: Sudapyridine
Normalized name: Sudapyridine
DrugBank: Sudapyridine (DB18984)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sudapyridine (WX-081) will be administered as a loading dose for 2 weeks (450 mg once daily for 7 days, followed by 300 mg once daily for 7 days) and a maintenance dose (150 mg once daily) from Week 3 to Week 24. The intervention is combined with background regimen (BR) and placebo for bedaquiline.
Study: NCT05824871
Drug: Bedaquiline
Normalized name: Bedaquiline
DrugBank: Bedaquiline (DB08903)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bedaquiline will be administered as a loading dose for 2 weeks (400 mg once daily) and a maintenance dose (200 mg three times per week, with at least 48 hours between doses) from Week 3 to Week 24. The intervention is combined with background regimen (BR) and placebo for Sudapyridine.
Study: NCT06025344
Drug: Probenecid 500 mg
Normalized name: probenecid 500 MG
DrugBank: Probenecid (DB01032)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single oral dose of 1000 mg under fasted conditions
Study: NCT05683990
Drug: Diamyd
DrugBank: rhGAD65 (DB04963)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 μg (0.1 mL) of Diamyd administered 1 month apart.
Study: NCT05273944
Drug: Doxorubicin Hydrochloride Liposome Injection
Normalized name: doxorubicin hydrochloride liposome Injection
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg/m2, intravenous drip on Day 1 of each cycle. On Day 1 of Cycle 1 patients will receive either reference or test product. On Day 1 of Cycle 2, patients will crossover to the alternate reference or test formulation. To measure pharmacokinetic paratemers of Caelyx® versus Lipodox®.
Study: NCT06067776
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT06067776
Drug: Tucatinib
Normalized name: Tucatinib
DrugBank: Tucatinib (DB11652)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT04785950
Drug: Low-dose levonorgestrel intrauterine systems (LNG-IUS)
Normalized name: levonorgestrel Intrauterine System
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Any low-dose intrauterine system (IUS) marketed in Spain
Study: NCT06082635
Drug: Crizotinib
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will be treated with the control drug crizotinib at 250 mg twice a day in 28-day cycles
Study: NCT05009862
Drug: Rivaroxaban 2.5 Mg Oral Tablet
Normalized name: rivaroxaban 2.5 MG Oral Tablet
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: rivaroxaban 2.5 milligrams twice daily
Study: NCT06698744
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 3 days of IV fludarabine 30 mg/m2 days -5 to -3 or -4 to -2 where day 0 is the day of CAR T-cell infusion.
Study: NCT06699329
Drug: Enlicitide Decanoate
Normalized name: decanoic acid
DrugBank: Capric acid (DB03600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple doses, oral tablet
Study: NCT06699329
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: multiple doses, oral tablet
Study: NCT06699836
Drug: 350 mg leronlimab
Normalized name: Leronlimab
DrugBank: Leronlimab (DB05941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
Study: NCT06699836
Drug: 700 mg leronlimab
Normalized name: Leronlimab
DrugBank: Leronlimab (DB05941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
Study: NCT06698965
Drug: Trilaciclib
Normalized name: Trilaciclib
DrugBank: Trilaciclib (DB15442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trilaciclib: 240mg/m2, Q3W, intravenous infusion should be completed within 4 hours before daily chemotherapy
Study: NCT04919811
Drug: Taletrectinib
Normalized name: taletrectinib
DrugBank: taletrectinib (DB18711)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg or 600mg QD
Study: NCT05532501
Drug: Oral Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administer oxytocin (24 IU) orally, 6 individual 0.1 ml puffs (4 IU/0.1ml) on the tongue (lingual), one every 30 seconds
Study: NCT05532501
Drug: Intranasal Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administer oxytocin (24 IU) intranasally, 6 individual 0.1 ml puffs (4 IU/0.1ml), three puffs per nostril one every 30 seconds
Study: NCT05121142
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib will be given by mouth or enteral tube (if applicable).
Study: NCT04790331
Drug: Verapamil
Normalized name: Verapamil
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina
Study: NCT04790331
Drug: Diltiazem
Normalized name: Diltiazem
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem is a calcium channel blocker. It works by relaxing the muscles of your heart and blood vessels.~Diltiazem is used to treat hypertension and angina.
Study: NCT00002235
Drug: Indinavir sulfate
Normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002235
Drug: Nelfinavir mesylate
Normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002235
Drug: Efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05179265
Drug: Human serum albumin
Normalized name: Human serum albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g/bottle (20%, 50 mL)
Study: NCT04433780
Drug: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate
Normalized name: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DOR/3TC/TDF 100/300/300 mg once daily fixed-dose combination switched from either EFV/TDF/FTC or DTG/TDF/3TC
Study: NCT04918719
Drug: Acetylcysteine
Normalized name: Acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The dosing of Acetylcysteine will be similar to the standard intravenous acetaminophen toxicity dosing: 150mg/kg in 200 milliliters of 5% Dextrose (D5W) infused over 1 hour, immediately followed by 50mg/kg in 500mL D5W infused over 4 hours, then 100mg/kg in 1000 milliliters D5W infused over 16 hours. (Any patient receiving t-PA who enrolls in the study will have their study drug infusion delayed by 24 hours after the completion of the t-PA infusion. )
Study: NCT04918719
Drug: Dextrose in Water
Normalized name: dextrose in water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will consist of a 5% Dextrose in Water instead of NAC (dosage and timigs are the same as the NAC arm). (Any patient receiving t-PA who enrolls in the study will have their study drug infusion delayed by 24 hours after the completion of the t-PA infusion. )
Study: NCT05308732
Drug: Copaiba
Normalized name: COPAIBA OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 10% and 15% aqueous solution of copaiba (Copaifera Officinalis Resin) manufactured by Interativo Farmácia de Manipulação will be used, under the formula: 10% copaiba oil (Copaifera Officinalis Resin) and 15% liquid mint aroma 5% , tween 80 1%, Aqueous solution (Distilled water + 0.1% Nipagin) qsp 100%.
Study: NCT05603598
Drug: LEAP-2 Protein, Human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion, mixed meal test, ad libitum meal test
Study: NCT06026501
Drug: PE0116,PE0105
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. PE0116: 4-1BB Agonist Antibody Drug~2. PE0105: PD-1 Monoclonal Antibody Drug
Study: NCT05829655
Drug: Drug A (Blinded Drug)
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
Study: NCT05829655
Drug: Drug B (Blinded Drug)
Normalized name: INVESTIGATIONAL ANTI-VIRAL DRUGS HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
Study: NCT05829655
Drug: Drug C (Blinded Drug)
Normalized name: Synovex C Drug Implant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
Study: NCT05829655
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double blind administration of placebo once per day during residential stay until discharge.
Study: NCT06052696
Drug: Gardasil 9 Suspension for Injection
Normalized name: Gardasil 9 Suspension for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: After randomisation in the Gardasil arm, women will receive 3 Gardasil vaccinations~1. First injection: preferable at time of start treatment (imiquimod, lase or surgery). Window 4 weeks prior to treatment start (because surgical treatment can be postponed for logistical reasons) and 4 weeks after start treatment.~2. Second injection: should be administered at least 1 month after the first injection and 3 months before the third injection.~3. Third injection should be administered at 3 months after second injection. All injections should be administered within 1 year.
Study: NCT06052696
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After randomisation in the PLacebo arm, women will receive 3 Placebo vaccination with NaCl 0.9%~1. First injection: preferable at time of start treatment (imiquimod, lase or surgery). Window 4 weeks prior to treatment start (because surgical treatment can be postponed for logistical reasons) and 4 weeks after start treatment.~2. Second injection: should be administered at least 1 month after the first injection and 3 months before the third injection.~3. Third injection should be administered at 3 months after second injection. All injections should be administered within 1 year.
Study: NCT05390840
Drug: MG-O-1002
Normalized name: citric acid 1002 MG
DrugBank: Citric acid (DB04272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MG-O-1002 ophthalmic solution in one concentration (0.8%) ocular administration 3 drops in study eye
Study: NCT04803955
Drug: 16mg，KB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16mg,Q8h±3min,Day1-Day7
Study: NCT04803955
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16mg,Q8h±3min,Day1-Day7
Study: NCT06140537
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo one tablet orally daily
Study: NCT05395260
Drug: FL-101
Normalized name: OXT-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: FL-101 200mg IV
Study: NCT05131555
Drug: Placebo: Placebo + exercise training.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo Exercise training: Interval-based cycling exercise
Study: NCT05131555
Drug: H1 blockade: H1 receptor antagonist + exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1 blockade: oral blockade Exercise training: Interval-based cycling exercise
Study: NCT05131555
Drug: H2 Blockade: H2 receptor antagonist + exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2 blockade: oral blockade Exercise training: Interval-based cycling exercise
Study: NCT05099159
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo orally once daily
Study: NCT04932096
Drug: melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: melatonin supplementation
Study: NCT05040360
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT05389215
Drug: DWN12088
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWN12088 Xmg Tablet (BID)
Study: NCT05389215
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 0mg Tablet (BID)
Study: NCT03134131
Drug: ONC201
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONC201 is an oral, small molecule selective antagonist of DRD2 that induces tumor cell death.
Study: NCT06304779
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: atients receive an equivalent volume of normal saline at anesthesia induction and throughout the perioperative period until 24 hours postoperatively.
Study: NCT04088591
Drug: Ascorbic Acid 500Mg/Ml Inj
Normalized name: ASCORBIC ACID 500MG/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascorbic acid 200mg/kg/day administered upon suspicion or confirmation of sepsis every 6 hours for a total duration of 96 hours
Study: NCT05797597
Drug: Aspirin 300 Mg Oral Tablet
Normalized name: aspirin 300 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-week treatment of aspirin, then after 2-weeks washout the next treatment arm is placebo for 8 weeks
Study: NCT05797597
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-week treatment of placebo, then after 2-weeks washout the next treatment arm is aspirin for 8 weeks
Study: NCT05556577
Drug: investigational medicine product (IMP)
Normalized name: Medicaine Sting Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational medicine product (IMP) received at SURMOUNT-CN trial